2025 San Antonio Breast Cancer Symposium (SABCS 2025)

San Antonio, Texas, US 09 December 2025 - 12 December 2025

Use of sacituzumab govitecan safe, efficacious in pretreated mBC

20 Jan 2026 by

A recent China study has provided further evidence on the real-world efficacy and safety of sacituzumab govitecan (SG) in HR+/HER2- and triple-negative breast cancer (TNBC) patients who have received at least three lines of prior therapy.

20 Jan 2026

Cruciferous veggies protective against breast cancer?

20 Jan 2026 by

An analysis using data from two large prospective studies demonstrates the protective effect of cruciferous vegetable consumption against breast cancer.

20 Jan 2026

5-year data back omission of sentinel lymph node biopsy in early-stage breast cancer

19 Jan 2026 by

Sentinel lymph node biopsy (SLNB) may be safely omitted after breast-conserving therapy in patients with early-stage, node-negative breast cancer, with 5-year data from the BOOG 13-08 trial showing no difference in regional recurrence-free and distant disease-free survival outcomes whether or not SLNB was performed.

19 Jan 2026

Sacituzumab govitecan proves real-world survival benefits in metastatic breast cancer

19 Jan 2026 by

A real-world study of the antibody-drug conjugate (ADC) sacituzumab govitecan in patients with HR+/ HER2- metastatic breast cancer (mBC) or metastatic triple-negative breast cancer (mTNBC) shows consistent survival outcomes as those seen in clinical trials.

19 Jan 2026

No rise in breast cancer risk for young BRCA carriers on menopausal hormone therapy

18 Jan 2026 by

For young women with a pathogenic variant in BRCA1 or BRCA2, initiating hormone replacement therapy following surgical menopause does not appear to significantly increase the risk of breast cancer, with oestrogen-alone therapy even conferring protection, according to a study.

18 Jan 2026

EPIK-B5 supports alpelisib plus fulvestrant for HR+, HER2– ABC

15 Jan 2026 by

In the phase III EPIK-B5 study, adding alpelisib, an α-specific PI3K inhibitor, to fulvestrant improves progression-free survival (PFS) in men and postmenopausal women with HR+, HER2− advanced breast cancer (ABC) harbouring a PIK3CA mutation who have progressed on or after treatment with an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i).

15 Jan 2026